This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The data presented in this study are available in this article.
References
Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469–73. https://doi.org/10.1016/s1084-2756(03)00119-2
Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367:2515–26. https://doi.org/10.1056/NEJMra1208129
Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group, B-RC. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15. https://doi.org/10.1056/NEJMoa1007374
Hard AL, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment—a review. Acta Paediatr. 2011;100:1523–7. https://doi.org/10.1111/j.1651-2227.2011.02445.x
Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327–33. https://doi.org/10.1016/j.ajo.2011.07.005. e321
Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol. 2002;283:L555–62. https://doi.org/10.1152/ajplung.00408.2001
Liotta M, Rose PG, Escobar PF. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer. Gynecol Oncol. 2009;115:308–9. https://doi.org/10.1016/j.ygyno.2009.08.003
Doxey S, Radwan A, Nyp MF. Outcomes of infants with severe ROP at risk of treatment with Avastin compared to laser surgery, https://scholarlyexchange.childrensmercy.org/cgi/viewcontent.cgi?article=1195&context=researchdays. 2021.
Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol. 2010;661:323–35. https://doi.org/10.1007/978-1-60761-500-2_21
Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology. 2007;91:283–90.
Acknowledgements
The authors would like to thank the funding sources. This work was supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 5 R01 HD072929 09 (SL), Children’s Miracle Network Grant at UC Davis Children’s Hospital (DS).
Author information
Authors and Affiliations
Contributions
LP drafted the initial manuscript. LP, LD, SL, and DS contributed to the concept, design, reviewed, and revised the manuscript. All the authors have critically revised and approved the final version of the manuscript. All authors agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
41372_2022_1489_MOESM2_ESM.jpg
Supplement Table 2: Description of echocardiographic features, respiratory support, and pulmonary vasodilator therapy before and after intravitreal bevacizumab treatment for ROP.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Park, L., Donohue, L., Lakshminrusimha, S. et al. Intravitreal bevacizumab injection for retinopathy of prematurity and pulmonary hypertension. J Perinatol 43, 236–237 (2023). https://doi.org/10.1038/s41372-022-01489-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-022-01489-0